FMP

FMP

Enter

AQST - Aquestive Therapeutics, Inc.

Profile of Aquestive Therapeutics, Inc.(AQST), Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and comm

photo-url-https://financialmodelingprep.com/image-stock/AQST.png

Aquestive Therapeutics, Inc.

AQST

NASDAQ

4.26 USD

0.16 (3.76%)

About

ceo

Mr. Daniel Barber

sector

Healthcare

industry

Drug Manufacturers - Specialty & Generic

website

https://www.aquestive.com

exchange

NASDAQ

Description

Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. The company's proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. Its proprietary pipeline of complex molecule products include AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; AQST-305, a sublingual film formulation of octreotide for the treatment of acromegaly; and AQST-109, an orally delivered epinephrine product candidate for the emergency treatment of allergic reactions, including anaphylaxis. Further, the company develops KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease. Aquestive Therapeutics, Inc. was incorporated in 2004 and is headquartered in Warren, New Jersey.

CIK

0001398733

ISIN

US03843E1047

CUSIP

03843E104

Address

30 Technology Drive

Phone

908 941 1900

Country

US

Employee

135

IPO Date

Jul 25, 2018

Key Executives

page loading card
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep